High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.09B
+29.28%
-0.934
+50.57%
3.09B
+1.33%
0.330
-64.13%
3.09B
+7.75%
-0.043
-95.13%
Estimates Revision
The market is revising Downward the revenue expectations for Oscar Health, Inc. (OSCR) for FY2025, with the revenue forecasts being adjusted by -0.33% over the past three months. During the same period, the stock price has changed by -14.41%.
Revenue Estimates for FY2025
Revise Downward
-0.33%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-5.96%
In Past 3 Month
Stock Price
Go Down
-14.41%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast OSCR.N stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR.N is 13.82 USD with a low forecast of 11.00 USD and a high forecast of 19.29 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
3 Sell
Moderate Sell
Current: 14.250
Low
11.00
Averages
13.82
High
19.29
Current: 14.250
Low
11.00
Averages
13.82
High
19.29
Wells Fargo
Underweight
downgrade
$14 -> $11
2025-11-13
New
Reason
Wells Fargo
Price Target
$14 -> $11
2025-11-13
New
downgrade
Underweight
Reason
Wells Fargo lowered the firm's price target on Oscar Health to $11 from $14 on lower odds for enhanced subsidy extension, while keeping an Underweight rating on the shares. The firm is updating estimates and model assumptions following Q3 and greater visibility into 2026 market dynamics. Wells sees Oscar Health as a clear share gainer in 2026, making it harder to underwrite MLR improvement.
Barclays
Andrew Mok
Underweight
maintain
$11 -> $13
2025-11-10
Reason
Barclays
Andrew Mok
Price Target
$11 -> $13
2025-11-10
maintain
Underweight
Reason
Barclays analyst Andrew Mok raised the firm's price target on Oscar Health to $13 from $11 and keeps an Underweight rating on the shares following the Q3 report. The company is putting though a weighted-average rate increase of 28%, with more competitive products in bronze and gold tiers, the analyst tells investors in a research note.
UBS
Sell
maintain
$11 -> $12
2025-11-07
Reason
UBS
Price Target
$11 -> $12
2025-11-07
maintain
Sell
Reason
UBS raised the firm's price target on Oscar Health to $12 from $11 and keeps a Sell rating on the shares.
Goldman Sachs
Neutral
initiated
$17
2025-10-14
Reason
Goldman Sachs
Price Target
$17
2025-10-14
initiated
Neutral
Reason
Goldman Sachs initiated coverage of Oscar Health with a Neutral rating and $17 price target. The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
Piper Sandler
Jessica Tassan
Neutral
downgrade
$14 -> $13
2025-08-14
Reason
Piper Sandler
Jessica Tassan
Price Target
$14 -> $13
2025-08-14
downgrade
Neutral
Reason
Piper Sandler analyst Jessica Tassan lowered the firm's price target on Oscar Health to $13 from $14 and keeps a Neutral rating on the shares. The firm notes the company reported mixed Q2 results last week, affirmed the revised 2025 guidance issued with the company's July 22 preannouncement and articulated expectations for a return to profitability in 2026. Piper acknowledges significant questions around the revised 2025 guide and 2026 path to profitability.
Baird
Outperform -> Neutral
downgrade
$28 -> $14
2025-07-25
Reason
Baird
Price Target
$28 -> $14
2025-07-25
downgrade
Outperform -> Neutral
Reason
Baird downgraded Oscar Health to Neutral from Outperform with a price target of $14, down from $28. The firm cites its caution on the healthcare exchange end market for the downgrade. Given Oscar's recent pre-announced Q2 and 2025 outlook revision, Baird is increasingly cautious into 2026 and beyond. There is now significant complexity in projecting Oscar's risk adjustment revenue, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Oscar Health Inc (OSCR.N) is -20.05, compared to its 5-year average forward P/E of 26.83. For a more detailed relative valuation and DCF analysis to assess Oscar Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
26.83
Current PE
-20.05
Overvalued PE
91.24
Undervalued PE
-37.58
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.42
Current EV/EBITDA
-48.42
Overvalued EV/EBITDA
9.97
Undervalued EV/EBITDA
-9.13
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.68
Current PS
13.88
Overvalued PS
2.45
Undervalued PS
-1.08
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
OSCR.N News & Events
Events Timeline
(ET)
2025-11-10
12:00:55
Oscar Health Experiences a 14.3% Decline
2025-11-06 (ET)
2025-11-06
08:33:44
Oscar Health expresses confidence in achieving profitability by 2026.
2025-11-06
06:08:06
Oscar Health projects FY25 revenue between $12.0B and $12.2B, in line with consensus of $12.04B
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/de01518d98817c8449182529487bfc75a2998fdb30a3245261656bf62494ea33.png)
Preview
8.5
11-15Yahoo FinanceAlphabet's Hidden Investments Have Acquired These 2 Stocks. Should You Consider Buying Them as Well?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/e8709889f8b7a8b74064e2e24bc73cdcdeba8c3e2ab45833640784fca4d87f9d.png)
Preview
8.0
11-14BenzingaOptions Corner: Oscar Health's Collapse Reveals Bold Informational Arbitrage
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/94e13dca6c020e489bdc4676a4d8c944d6ca740579f236cc2af58db1ab41406d.jpg)
Preview
6.0
11-13BenzingaWells Fargo Keeps Underweight Rating on Oscar Health, Reduces Price Target to $11
Sign Up For More News
People Also Watch
FAQ
What is Oscar Health Inc (OSCR.N) stock price today?
What is Oscar Health Inc (OSCR.N)'s business?
What is the price predicton of OSCR.N Stock?
What is Oscar Health Inc (OSCR.N)'s revenue for the last quarter?
What is Oscar Health Inc (OSCR.N)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Oscar Health Inc (OSCR.N)'s fundamentals?
How many employees does Oscar Health Inc (OSCR.N). have?